KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Biomarin Pharmaceutical (BMRN) Inventory (2016 - 2025)

Biomarin Pharmaceutical (BMRN) has disclosed Inventory for 17 consecutive years, with $1.3 billion as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Inventory rose 5.37% year-over-year to $1.3 billion, compared with a TTM value of $1.3 billion through Dec 2025, up 5.37%, and an annual FY2025 reading of $1.3 billion, up 5.37% over the prior year.
  • Inventory was $1.3 billion for Q4 2025 at Biomarin Pharmaceutical, down from $1.4 billion in the prior quarter.
  • Across five years, Inventory topped out at $1.4 billion in Q3 2025 and bottomed at $713.9 million in Q1 2021.
  • Average Inventory over 5 years is $1.0 billion, with a median of $1.0 billion recorded in 2023.
  • The sharpest move saw Inventory grew 23.84% in 2024, then rose 5.37% in 2025.
  • Year by year, Inventory stood at $776.7 million in 2021, then increased by 15.12% to $894.1 million in 2022, then increased by 23.83% to $1.1 billion in 2023, then increased by 11.33% to $1.2 billion in 2024, then grew by 5.37% to $1.3 billion in 2025.
  • Business Quant data shows Inventory for BMRN at $1.3 billion in Q4 2025, $1.4 billion in Q3 2025, and $1.3 billion in Q2 2025.